David H. Fine, PhD

Chairman and Chief Scientific Officer

Dr. David H. Fine is the founder and Chairman and Chief Scientific Officer of GeNO. From inception until December 2011, he was President and from inception until August 2013 he was Chief Executive Officer. Dr. Fine has served as a Manager of GeNO since 2006.

Dr. Fine has 40 years of experience leading innovation development and transitioning high technology chemistry-based instruments from research through production and into commercialization. In 2000, Dr. Fine co-founded CyTerra Corporation, a company focused on advanced technology for the detection of buried land mines. Dr. Fine served as Chief Executive Officer of CyTerra from 2000 until 2006. Prior to co-founding CyTerra, Dr. Fine worked for 28 years at Thermo Electron Corporation. During his tenure at Thermo Electron, Dr. Fine published extensively on the formation of carcinogenic N-nitrosamines, the detection of NO and NO2 using chemiluminescence, the detection of explosives for forensic and airport security by converting them to NO, and then measuring the NO, and many other detection systems using the NO moiety. Dr. Fine held various leadership positions at Thermo Electron, including Vice President of Thermedics Inc. and Senior Vice President of Thermedics Detection Inc., both of which were publicly-traded subsidiaries of Thermo Electron. His last assignment at Thermo Electron was as President of Thermo Electron’s R&D Center Inc. From 1969 to 1972, while on the academic staff of the Chemical Engineering Department at MIT, Dr. Fine worked on the formation and mitigation of NO formed in combustion systems and NO related air pollution chemistry. Dr. Fine has published over 100 technical papers in refereed technical literature, including Nature and Science. He is also the inventor on 71 issued U.S. patents including over 50 patents on NO/NO2 based chemistry and instrumentation.

Kurt Dasse, PhD

President and Chief Executive Officer

Dr. Kurt A. Dasse is the President and Chief Executive Officer of GeNO. He became Executive Vice President in December 2011, President in December 2012 and Chief Executive Officer in August 2013. From 2007 to 2011, Dr. Dasse served as a non-employee member of our Board of Managers and has remained a Manager since joining the Company in an executive capacity in 2011.

Dr. Dasse has spent nearly three decades conducting research in cardiovascular disorders and developing products to treat heart and renal failure. He has extensive experience in designing, developing and commercializing products and in obtaining the required regulatory approvals. From 2006 to 2011, he served as President and CEO of Levitronix LLC, a developer and manufacturer of a new generation of blood pumps for the medical industry, including the CentriMag, PediMag and PediVAS devices, and ultra-pure fluid handling components for the semiconductor industry. The medical business of Levitronix was sold to Thoratec Corp. in August 2011. From 2000 to 2006, Dr. Dasse served as President of the Medical Division of Levitronix, LLC. From 1997 to 2000, Dr. Dasse was Chief Scientist and Vice-President of Thermo Electron Corporation’s Biomedical Group, where he focused on developing products for the respiratory, neurodiagnostic, cardiovascular and imaging markets. He also was one of the founding officers of Thermo Cardiosystems and played a key role in the development and commercialization of the original HeartMate LVAD, the first implantable ventricular assist system for end-stage heart-failure patients. Dr. Dasse has written more than 100 journal articles and multiple book chapters and holds multiple patents. Dr. Dasse has extensive experience in winning 510(k)’s, IDE’s, PMA’s, CE Marks and international approvals for devices such as blood pumps, ventricular assist systems, drive consoles, peritoneal dialysis catheters, digital mammography equipment and software.


Mark Wedel, MD, JD

Chief Medical Officer and Vice-President of Clinical Affairs

Dr. Mark Wedel is Chief Medical Officer & Vice-President of Clinical Affairs at GeNO. A graduate of the Johns Hopkins School of Medicine and the Thomas Jefferson School of Law, Dr. Wedel is a critical care physician who served as director of the medical-surgical intensive care unit at Scripps Green Hospital in La Jolla, California before embarking on a distinguished career in biotechnology & drug development. Dr. Wedel lead the Phase III trials of liquid ventilation in ARDS for Alliance Pharmaceutical, was Chief Medical Officer & Senior Vice President of Clinical Development for Isis Pharmaceuticals where he directed the Phase II program that resulted in the licensing of mipomersen, the first antisense oligonucleotide to receive FDA approval, and subsequently at Santaris he designed and initiated the microRNA IND and Hepatitis C trial of a microRNA that ultimately culminated in the licensing of its LNA technology by Glaxo Smith Kline. Dr. Wedel is the holder of several drug patents and the author of more than one hundred papers, abstracts & one book.

Anthony Loumidis, MBA

Chief Financial Officer and Treasurer

Mr. Loumidis was appointed as the Chief Financial Officer and Treasurer of GeNO in October 2013. He served as the Chief Financial Officer of American DG Energy Inc. from 2004 and Treasurer from 2001 until October, 2013.  He also served as Chief Financial Officer, Treasurer and Secretary of Eurosite Power Inc. from 2010 to October 2013, and as Vice President and Treasurer of Tecogen Inc., an affiliate of American DG Energy Inc., from 2001 to October 2013.  Prior to 2001, Mr. Loumidis held various positions at Thermo Electron, including National Sales Manager for Thermo Capital Financial Services, Manager of Investor Relations and Manager of Business Development of Tecomet, a subsidiary of Thermo Electron.

Farzad Parsaie, MBA

Chief Operating Officer

Mr. Parsaie was appointed as the Chief Operating Officer of GeNO in October 2013. Mr. Parsaie has over 20 years of experience in the medical device industry and has extensive experience managing projects and operations and commercializing products in FDA regulated environments. Since 2011, Mr. Parsaie has consulted for medical device, pharmaceutical and nutrition firms in the quality assurance, regulatory affairs, and product strategy domains. From 2007 to 2011, Mr. Parsaie served as the Chief Operating Officer-U.S. for Levitronix LLC, a developer and manufacturer of a new generation of blood pumps for the medical industry, and ultra-pure fluid handling components for the semiconductor industry. Prior to 2007, Mr. Parsaie held management positions in quality assurance, regulatory affairs, research and development, program management and marketing at Boston Scientific, Thermo Cardiosystems, Medtronic and CR Bard.

Jack Whiting, JD, MBA

Vice-President, General Counsel and Secretary

Mr. Whiting joined GeNO in 2011 as Vice President of Operations, served as Vice-President of Administration, and was appointed Vice-President, General Counsel & Secretary in 2013. He served as Vice-President, General Counsel, and Secretary of Levitronix LLC, a developer and manufacturer of blood pumps for the medical industry and ultra-pure fluid handling components for the semiconductor industry, from 2009 until 2011, Vice-President and General Counsel of American Renal Associates Inc., a provider of kidney dialysis services, from 2002 to 2008, Associate General Counsel at Thermo Electron Corporation (now Thermo Fisher Scientific), a manufacturer of medical, energy, and other technologies, from 1996 to 2002, Assistant General Counsel at National Medical Care Inc. (now Fresenius Medical Care), a provider of kidney dialysis services and products, from 1991 to 1996, and as legal counsel at law firms from 1986 to 1991. Mr. Whiting has almost 30 years of experience providing legal and business support for both public and private companies, primarily in medical device, medical services, and pharmaceutical businesses.